BIMEKIZUMAB MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Bimekizumab Market, By Indication (Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Non-radiographic axial spondyloarthritis (nraxSpA), and Other Investigational Autoimmune Indications), By Age Group (Adult and Geriatric), By Gender (Male and Female), By End User (Hospitals, Dermatology Clinics, Rheumatology Clinics, and Specialty Care Centers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Published In: 19 Dec, 2025
Code: CMI9110
Pages: 168
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range: 2020 - 2024
- Forecast Period: 2025 - 2032

The global bimekizumab market is estimated to be valued at USD 1.52 Bn in 2025 and is expected to reach USD 5.61 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 20.5% from 2025 to 2032. Global bimekizumab market represents a rapidly evolving segment within biopharmaceutical industry, centered around a novel monoclonal antibody therapeutic that selectively inhibits both interleukin-17A and interleukin-17F cytokines. Bimekizumab, developed as an innovative immunomodulatory agent, has emerged as a promising treatment option for various autoimmune inflammatory conditions, particularly psoriasis, psoriatic arthritis, ankylosing spondylitis, and other related inflammatory disorders. This dual IL-17A/F inhibition mechanism distinguishes bimekizumab from existing IL-17 inhibitors, potentially offering enhanced therapeutic efficacy and improved patient outcomes.

The market's growth trajectory is primarily driven by increasing prevalence of autoimmune diseases globally, rising awareness about advanced biologic therapies, and growing demand for targeted immunotherapy solutions. Regulatory approvals across major pharmaceutical markets have positioned bimekizumab as a significant competitor in the biologic therapeutics landscape. The pharmaceutical industry's continued focus on precision medicine and personalized treatment approaches has further accelerated market adoption. Healthcare providers increasingly recognize the potential benefits of dual cytokine inhibition compared to traditional single-target therapies, contributing to expanding clinical applications and market penetration across diverse patient populations seeking effective long-term management of chronic inflammatory conditions.

Market Dynamics

The global bimekizumab market experiences robust growth driven by several key factors, including the escalating worldwide prevalence of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis, which collectively affect millions of patients seeking effective treatment alternatives. The superior efficacy profile demonstrated in clinical trials, particularly the dual IL-17A/F inhibition mechanism that provides enhanced therapeutic outcomes compared to single-target competitors, serves as a primary market driver alongside increasing healthcare expenditure and growing adoption of biologic therapies. Rising awareness among healthcare professionals about advanced immunomodulatory treatments and expanding diagnostic capabilities contribute to market expansion, while favorable reimbursement policies in developed markets facilitate patient access.

However, market growth faces significant restraints including the exceptionally high cost of biologic therapies that limits accessibility, particularly in emerging economies with constrained healthcare budgets, stringent regulatory approval processes requiring extensive clinical evidence, potential safety concerns associated with immunosuppression including increased infection risks, and intense competition from established IL-17 inhibitors and other biologic alternatives. Manufacturing complexities and supply chain challenges for monoclonal antibodies also pose operational constraints.

Nevertheless, substantial opportunities emerge through expanding applications to additional autoimmune indications currently under clinical investigation, growing market penetration in emerging economies with improving healthcare infrastructure, development of combination therapies that could enhance treatment outcomes, increasing focus on personalized medicine approaches, and potential biosimilar development following patent expiration that could improve market accessibility and affordability for broader patient populations.

Key Features of the Study

This report provides in-depth analysis of the global bimekizumab market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bimekizumab market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key company covered as a part of this study include UCB
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global bimekizumab market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bimekizumab market

Market Segmentation

Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Plaque Psoriasis
- Psoriatic Arthritis
- Axial Spondyloarthritis
- Non-radiographic axial spondyloarthritis (nraxSpA)
- Other Investigational Autoimmune Indications
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Geriatric
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Dermatology Clinics
- Rheumatology Clinics
- Specialty Care Centers
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - North Africa
  - Central Africa
Key Players Insights
- UCB

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Global Bimekizumab Market, By Indication
  - Global Bimekizumab Market, By Age Group
  - Global Bimekizumab Market, By Gender
  - Global Bimekizumab Market, By End User
  - Global Bimekizumab Market, By Distribution Channel
  - Global Bimekizumab Market, By Region
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Industry Trends
Global Bimekizumab Market, By Indication, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Plaque Psoriasis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Psoriatic Arthritis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Axial Spondyloarthritis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Non-radiographic axial spondyloarthritis (nraxSpA)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Investigational Autoimmune Indications
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Bimekizumab Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Adult
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Bimekizumab Market, By Gender, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Male
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Bimekizumab Market, By End User, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Hospitals
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dermatology Clinics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rheumatology Clinics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Care Centers
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Bimekizumab Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Bimekizumab Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
  - Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  - Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - Brazil
    - Argentina
    - Mexico
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - Germany
    - U.K.
    - Spain
    - France
    - Italy
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - GCC Countries
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    - South Africa
    - North Africa
    - Central Africa
Competitive Landscape
- UCB
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
References and Research Methodology
- References
- Research Methodology
- About us

*Browse 32 market data tables and 28 figures on ‘Bimekizumab Market' - Global forecast to 2032

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now